CD274 and non-small cell lung carcinoma: Currently, immunotherapy against the PD-1/PD-L1 axis is the first-line or subsequent treatment option for NSCLC patients and PD-1/PD-L1 antibodies, including pembrolizumab, nivolumab, atezolizumab, and durvalumab (Herbst et al., 2020).